ArticleBioMed research international2021
Intratumoral STING Agonist Injection Combined with Irreversible Electroporation Delays Tumor Growth in a Model of Hepatocarcinoma.
Article in BioMed research international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Molecular mechanisms and therapeutic strategies of cGAS-STING pathway in liver disease: the quest continues.Frontiers in immunology · 2025Pooled it
- Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.Current oncology reports · 2026Review
- CD40 agonist improves the therapeutic efficacy of irreversible electroporation ablation for metastatic melanoma by promoting unexpected CD8Cancer immunology, immunotherapy : CII · 2025Article
- Bidirectional regulation of the cyclic guanosine monophosphate-adenosine monophosphate synthase-stimulator of interferon gene pathway and its impact on hepatocellular carcinoma.World journal of gastrointestinal oncology · 2025Article
- The 41BB-agonist potentiates the therapeutic efficacy of a combined irreversible electroporation ablation treatment of lung cancer by promoting unexpected CD8Frontiers in immunology · 2025Article
- The dual function of cGAS-STING signaling axis in liver diseases.Acta pharmacologica Sinica · 2024Review
- Harnessing innate immune pathways for therapeutic advancement in cancer.Signal transduction and targeted therapy · 2024Review
- Update on the STING Signaling Pathway in Developing Nonalcoholic Fatty Liver Disease.Journal of clinical and translational hepatology · 2024Review
- Review
- Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma.Cell reports. Medicine · 2023Article
- [Irreversible electroporation: present and future in the treatment of hepatocellular carcinoma].Anales del sistema sanitario de Navarra · 2022Review
- Intratumoral electroporation of a self-amplifying RNA expressing IL-12 induces antitumor effects in mouse models of cancer.Molecular therapy. Nucleic acids · 2022Article
- Review
- Review
- Cyclic dinucleotides mediate bacterial immunity by dinucleotide cyclase inFrontiers in microbiology · 2022Review
- Irreversible Electroporation: An Emerging Immunomodulatory Therapy on Solid Tumors.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimIrreversible electroporation (IRE) showed promising results for small-size tumors and very early cancers. However, further development is needed to evolve this procedure into a more efficient ablation technique for long-term control of tumor growth. In this work, we show that it is possible to increase the antitumor efficiency of IRE by simmultaneously injecting c-di-GMP, a STING agonist, intratumorally. MATERIALS AND
methodsIntratumoral administration of c-di-GMP simultaneously to IRE was evaluated in murine models of melanona (B16.OVA) and hepatocellular carcinoma (PM299L).
resultsThe combined therapy increased the number of tumor-infiltrating IFN-
conclusionThese results can lead to the development of a new therapeutic strategy for the treatment of cancer patients refractory to other therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.